Aldeyra net loss narrows 44.2% to $5.45 million in Q2 2026

Reuters2026/08/06 20:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aldeyra Therapeutics posted a GAAP net loss of USD 5.45 million for Q2 2026, narrowing 44.2% from a loss of USD 9.77 million.
Operating loss improved 42.5% to USD 5.85 million, as research and development expense fell 59% to USD 3.48 million.
General and administrative expense rose 42.2% to USD 2.37 million, while interest income dropped 54.1% to USD 400,257.
Cash and cash equivalents totaled USD 45.1 million at June 30, 2026; the company said it expects funding into the second half of 2028.
AbbVie has not exercised its reproxalap option as of Aug. 6, 2026; Aldeyra repaid its USD 15 million Hercules loan on April 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001341235-26-000010), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aldeyra net loss narrows 44.2% to $5.45 million in Q2 2026

You may also like

Crypto prices